IN BRIEF: Apollon Formularies intends to withdraw from AQUIS

Apollon Formularies PLC - London-based medical cannabis pharmaceutical firm - On Wednesday, said ...

Alliance News 2 May, 2024 | 1:23PM
Email Form Facebook Twitter LinkedIn RSS

Apollon Formularies PLC - London-based medical cannabis pharmaceutical firm - On Wednesday, said intends to withdraw its shares from trading on the Aquis Growth Market, with the last day of trading expected to be on June 3. "The company continues to progress the divestment of its intellectual property, proprietary formulations and other assets associated with its cancer research business to a Canadian company in the same field," it says. Apollon adds: "There will be no alternative exchange or platform to trade the company's ordinary shares once withdrawal has taken place, however, the company will explore potential mechanisms for the ongoing sale and purchase of its ordinary shares using platforms tailored to unlisted companies. It has not yet identified such a platform."

Current stock price: 0.05 pence per share, down 29% on Thursday afternoon in London

12-month change: down 70%

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Apollon Formularies PLC 0.15 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures